MedTrace Logo

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

NCT01959529 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 7637

Last updated 2019-07-24

Study results available
· View outcomes & findings →

Summary

This trial is conducted globally. The aim of this trial is to compare cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.

Conditions

Interventions

DRUG

insulin degludec

Injected once daily subcutaneously (s.c., under the skin)

DRUG

insulin glargine

Injected once daily subcutaneously (s.c., under the skin)

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-29
Primary Completion
2016-10-16
Completion
2016-10-16

Countries

  • United States
  • Algeria
  • Argentina
  • Brazil
  • Canada
  • Croatia
  • Greece
  • India
  • Italy
  • Japan
  • Malaysia
  • Mexico
  • Poland
  • Romania
  • Russia
  • South Africa
  • South Korea
  • Spain
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01959529 on ClinicalTrials.gov